Table of Contents
Leukemia Research and Treatment
Volume 2012 (2012), Article ID 125814, 8 pages
http://dx.doi.org/10.1155/2012/125814
Review Article

Clinical Experience Using Vitamin D and Analogs in the Treatment of Myelodysplasia and Acute Myeloid Leukemia: A Review of the Literature

1Division of Hematology, Department of Medicine, Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA
2The Cancer Institute of New Jersey, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ 08901, USA

Received 1 March 2012; Revised 5 April 2012; Accepted 17 April 2012

Academic Editor: George P. Studzinski

Copyright © 2012 Jonathan S. Harrison and Alexander Bershadskiy. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. C. Medeiros, M. Othus, M. Fang, D. Roulston, and F. R. Appelbaum, “Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience,” Blood, vol. 116, no. 13, pp. 2224–2228, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. C. Miyaura, E. Abe, and T. Kuribayashi, “1α,25-dihydroxyvitamin D3 induces differentiation of human myeloid leukemia cells,” Biochemical and Biophysical Research Communications, vol. 102, no. 3, pp. 937–943, 1981. View at Google Scholar · View at Scopus
  3. M. Kim, L. Mirandola, A. Pandey et al., “Application of vitamin D and derivatives in hematological malignancies,” Cancer Letters, vol. 319, no. 1, pp. 8–22, 2012. View at Publisher · View at Google Scholar
  4. S. Irino and T. Taoka, “Treatment of myelodysplastic syndrome and acute myelogenous leukemia with Vit. D3 [1α(OH)D3],” Japanese Journal of Cancer and Chemotherapy, vol. 15, no. 4, pp. 1183–1190, 1988. View at Google Scholar · View at Scopus
  5. T. Takahashi, S. Ichiba, Y. Okuno et al., “Therapeutic effectiveness of vitamin D3 in patients with myelodysplastic syndromes, leukemias and myeloproliferative disorders,” The Japanese Journal of Clinical Hematology, vol. 30, no. 1, pp. 1–10, 1989. View at Google Scholar · View at Scopus
  6. H. P. Koeffler, K. Hirji, and L. Itri, “1,25-Dihydroxyvitamin D3: in vivo and in vitro effects on human preleukemic and leukemic cells,” Cancer Treatment Reports, vol. 69, no. 12, pp. 1399–1407, 1985. View at Google Scholar · View at Scopus
  7. S. Nakayama, T. Ishikawa, H. Yabe, K. Nagai, S. Kasakura, and H. Uchino, “Successful treatment of a patient with acute myeloid leukemia with 1α(OH)D3,” Acta Haematologica Japonica, vol. 51, no. 6, pp. 1026–1030, 1988. View at Google Scholar · View at Scopus
  8. S. Motomura, H. Kanamori, A. Maruta, F. Kodama, and T. Ohkubo, “The effect of 1-hydroxyvitamin D3 for prolongation of leukemic transformation-free survival in myelodysplastic syndromes,” American Journal of Hematology, vol. 38, no. 1, pp. 67–68, 1991. View at Google Scholar · View at Scopus
  9. L. Mellibovsky, A. Díez, E. Pérez-Vila et al., “Vitamin D treatment in myelodysplastic syndromes,” British Journal of Haematology, vol. 100, no. 3, pp. 516–520, 1998. View at Publisher · View at Google Scholar · View at Scopus
  10. G. J. Mufti, J. R. Stevens, and D. G. Oscier, “Myelodysplastic syndromes: a scoring system with prognostic significance,” British Journal of Haematology, vol. 59, no. 3, pp. 425–433, 1985. View at Google Scholar · View at Scopus
  11. Y. Yoshida, S. Oguma, H. Uchino, T. Maekawa, and T. Nomura, “A randomized study of alfacalcidol in the refractory myelodysplastic anaemias. A Japanese cooperative study,” International Journal of Clinical Pharmacology Research, vol. 13, no. 1, pp. 21–27, 1993. View at Google Scholar · View at Scopus
  12. A. Petrich, B. Kahl, H. Bailey, K. Kim, N. Turman, and M. Juckett, “Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome,” Leukemia and Lymphoma, vol. 49, no. 1, pp. 57–61, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. I. Blazsek, C. Farabos, M. Musset et al., “Retinoic acid in mono- or combined differentiation therapy of myelodysplasia and acute promyelocytic leukemia,” Biomedicine and Pharmacotherapy, vol. 45, no. 4-5, pp. 169–177, 1991. View at Google Scholar · View at Scopus
  14. T. Siitonen, T. Timonen, E. Juvonen et al., “Valproic acid combined with 13-cis retinoic acid and 1,25-dihydroxyvitamin D3 in the treatment of patients with myelodysplastic syndromes,” Haematologica, vol. 92, no. 8, pp. 1119–1122, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. E. Hellström, K. H. Robèrt, G. Gahrton et al., “Therapeutic effects of low-dose cytosine arabinoside, alpha-interferon, 1α-hydroxyvitamin D3 and retinoic acid in acute leukemia and myelodysplastic syndromes,” European Journal of Haematology, vol. 40, no. 5, pp. 449–459, 1988. View at Google Scholar · View at Scopus
  16. E. Hellström, K. H. Robèrt, J. Samuelsson et al., “Treatment of myelodysplastic syndromes with retinoic acid and 1α-hydroxy-vitamin D3 in combination with low-dose ara-C is not superior to ara-C alone. Results from a randomized study,” European Journal of Haematology, vol. 45, no. 5, pp. 255–261, 1990. View at Google Scholar · View at Scopus
  17. L. De Rosa, A. Montuoro, and A. De Laurenzi, “Therapy of “high risk” myelodysplastic syndromes with an association of low-dose Ara-C, retinoic acid and 1,25-dihydroxyvitamin D3,” Biomedicine and Pharmacotherapy, vol. 46, no. 5-7, pp. 211–217, 1992. View at Google Scholar · View at Scopus
  18. D. Ferrero, B. Bruno, P. Pregno et al., “Combined differentiating therapy for myelodysplastic syndromes: a phase II study,” Leukemia Research, vol. 20, no. 10, pp. 867–876, 1996. View at Publisher · View at Google Scholar · View at Scopus
  19. D. Ferrero, E. Campa, C. Dellacasa, S. Campana, C. Foli, and M. Boccadoro, “Differentiating agents + low-dose chemotherapy in the management of old/poor prognosis patients with acute myeloid leukemia or myelodysplastic syndrome,” Haematologica, vol. 89, no. 5, pp. 619–620, 2004. View at Google Scholar · View at Scopus
  20. C. A. Slapak, J. F. Desforges, T. Fogaren, and K. B. Miller, “Treatment of acute myeloid leukemia in the elderly with low-dose cytarabine, hydroxyurea, and calcitriol,” American Journal of Hematology, vol. 41, no. 3, pp. 178–183, 1992. View at Publisher · View at Google Scholar · View at Scopus
  21. D. Ferrero, A. Darbesio, V. Giai et al., “Efficacy of a combination of human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3 to improve moderate to severe anaemia in low/intermediate risk myelodysplastic syndromes,” British Journal of Haematology, vol. 144, no. 3, pp. 342–349, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. N. Akiyama, K. Miyazawa, Y. Kanda et al., “Multicenter phase II trial of vitamin K2 monotherapy and vitamin K2 plus 1α-hydroxyvitamin D3 combination therapy for low-risk myelodysplastic syndromes,” Leukemia Research, vol. 34, no. 9, pp. 1151–1157, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. B. D. Cheson, P. L. Greenberg, J. M. Bennett et al., “Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia,” Blood, vol. 108, no. 2, pp. 419–425, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. G. P. Studzinski, X. Wang, Y. Ji et al., “The rationale for deltanoids in therapy for myeloid leukemia: role of KSR-MAPK-C/EBP pathway,” Journal of Steroid Biochemistry and Molecular Biology, vol. 97, no. 1-2, pp. 47–55, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Wieder, S. C. Novick, B. W. Hollis et al., “Pharmacokinetics and safety of ILX23-7553, a non-calcemic-vitamin D 3 analogue, in a phase I study of patients with advanced malignancies,” Investigational New Drugs, vol. 21, no. 4, pp. 445–452, 2003. View at Publisher · View at Google Scholar · View at Scopus